ARTICLE | Product Development
More evidence it’s okay to delay second dose of COVID vaccines
This time from peer-reviewed AZ data and real-world data on Pfizer/BioNTech vaccine
February 20, 2021 3:18 AM UTC
New findings reported for COVID vaccines from partners Pfizer and BioNTech and AstraZeneca could better inform public health decisions on vaccine schedules by supporting the spacing out of first and second doses.
One study, reported Friday by Chaim Sheba Medical Centre and Tel Aviv University researchers in The Lancet, shows the efficacy of Comirnaty (BNT162b2) from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) rises quickly after the first dose. ...